An Open-Label, Multicenter, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• The investigators concluded that the participants continued to benefit from treatment with Jaktinib.
• The participants have been fully informed and voluntarily signed informed consent.
• The participants completed the ZGJAK029 study for 16 weeks of treatment and visitation and had good compliance.
• The interval between the participants' first dose and the last dose of ZGJAK029 ≤ 4 weeks.
Locations
Other Locations
China
Renji Hospital
RECRUITING
Shanghai
Contact Information
Primary
Bin Xie
xieb@zelgen.com
+86-0512-57018310
Time Frame
Start Date: 2023-11-10
Estimated Completion Date: 2025-12
Participants
Target number of participants: 258
Treatments
Experimental: Jaktinib 100mg BID (twice daily)
Related Therapeutic Areas
Sponsors
Leads: Suzhou Zelgen Biopharmaceuticals Co.,Ltd